Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a single chat with a partner keep people who inject drugs in care?

NCT ID NCT07631559

First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 2 times

Summary

This pilot study tests a one-time 'booster' session for people who inject drugs and their injecting partners, given right after finishing hepatitis C treatment. The session helps them set health goals, identify barriers, and improve communication to stay engaged in ongoing healthcare. Researchers will enroll 50 adults in San Francisco to see if the session is acceptable and feasible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C (HCV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Quaker Meeting House

    San Francisco, California, 94103, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

partner navigation intervention booster session

What this could lead to

If successful, this could point toward a simple, low-cost way to help people who inject drugs stay connected to healthcare after finishing hepatitis C treatment.

What could go wrong

This is a very small pilot study (50 people) testing only feasibility and acceptability, not whether the session actually improves health. It may not work in other settings or populations.

Conditions

The condition(s) this trial relates to.

Harm Reduction hepatitis C virus infection Opioid-Related Disorders Substance-Related Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.